International Case Reports Journal (ISSN: 2770-9647) | Volume 3, Issue 1 | Research Article | Open Access
Garcia Patricia J*
Garcia Patricia J1*, Moran Flavia F1, Ugarte-Gil Cesar2,3, León Patricia4, Chacaltana Jesus5, Málaga German3,4, Mundaca Hansel6, Dobaño Carlota6,7, Moncunill Gemma6,7, Chaccour Carlos6,7,8 and Cárcamo Cesar P1 1Department of Epidemiology, School of Public Health, Universidad Peruana Cayetano Heredia, Peru 2Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Peru 3School of Medicine, Universidad Peruana Cayetano Heredia, Peru 4Hospital Nacional Cayetano Heredia, Peru 5Hospital Nacional Daniel A. Carrión, Peru 6ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain 7CIBER de Enfermedades Infecciosas, Spain 8Facultad de Medicina, Universidad de Navarra, Spain
*Correspondence to: Garcia Patricia JFulltext PDF
Ivermectin was a popular drug used for COVID-19 in Latin America, although there was no clinical evidence about its efficacy. We conducted a randomized, placebo-controlled trial to evaluate the effect of ivermectin on the detection of SARS-CoV-2 RNA by PCR in non-severe COVID-19 patients in Peru. Patients with 96 hours of COVID-19 related symptoms were preselected at the emergency services of two national hospitals. Those eligible were randomized to one dose of 300 mcg/kg ivermectin or placebo daily for 3 days and were followed for 21 days. The primary outcome was the proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7. 22/24 in the placebo and 16/16 in the ivermectin arm (p=0.236) were PCR positive at day 7, and participants in the placebo arm had cycle threshold (Ct) values significantly higher compared to the ivermectin arm (p=0.028 and 0.014 for genes N1 and N2 respectively). There was no difference between arms in disease progression, adverse events, IgG seroconversion rate or median IgG titers at day 21. We found no difference in the PCR positivity between those treated with ivermectin or placebo suggesting no benefit from the use of ivermectin among patients with non-severe COVID-19.
COVID-19; Ivermectin; Randomized clinical trial
Patricia JG, Flavia FM, Cesar UG, Patricia L, Jesus C, German M, Hansel M, Carlota D, Gemma M, Carlos C, Cesar PC. Randomized Clinical Trial to Compare the Efficacy of Ivermectin Vs. Placebo to Negativize Nasopharyngeal Pcr in Patients with Early Covid-19 in Peru (Saint-Peru). Int Case Rep Jour. 2022;2(8):1-18.